SIETES :: 92806 citas

Resultados de la búsqueda por OXICODONA REFINAR BÚSQUEDA

1.

Podolsky SH, Herzberg D, Greene JA. Preying on prescribers (and their patients) — Pharmaceutical marketing, iatrogenic epidemics, and the Sackler legacy. N Engl J Med 2019:10 de abril. [Ref.ID 103090]

2.

Parthipan A, Banerjee I, Humphreys K, Asch SM, Curtin C, Carroll I, Hernandez-Boussard T. Predicting inadequate postoperative pain management in depressed patients: a machine learning approach. PLoS One 2019;14:6 de febrero. [Ref.ID 103058]

3.

Hedegaard H, Bastian BA, Trinidad JP, Spencer M, Warner M. Drugs most frequently involved in drug overdose deaths: United States, 2011–2016. National Vital Statistics Reports 2018;67:12 de diciembre. [Ref.ID 102871]

4.

Walters J. Una familia multimillonaria, señalada por la epidemia de opiáceos en EEUU . eldiario.es 2018:19 de noviembre. [Ref.ID 102852]

5.

Hider-Mlynarz K, Cavalié P, Maison P. Trends in analgesic consumption in France over the last 10 years and comparison of patterns across Europe. Br J Clin Pharmacol 2018;84:junio. [Ref.ID 102806]

6.

Floyd CN, Warren JB. Opioids out of control. Br J Clin Pharmacol 2018;84:mayo. [Ref.ID 102794]

7.

Krebs EE, Gravely A, Nugent S, Jensen AC, DeRonne B, Goldsmith ES, Kroenke K, Bair MJ, Noorbaloochi S. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee ostoarthritis pain. The SPACE randomized clinical trial. JAMA 2018;319:6 de marzo. [Ref.ID 102554]

8.

Moore PA, Ziegler KM, Lipman RD, Aminoshariae A, Carrasco-Labra A, Mariotti A. Benefits and harms associated with analgesic medications used in the management of acute dental pain. The Journal of the American Dental Association 2018;149:abril. [Ref.ID 102481]

9.

Anónimo. Senate investigation reveals five manufacturers funded groups that acted as opioid “cheerleaders.”. DIA Daily 2018:12. [Ref.ID 102455]

10.

Anónimo. Purdue to halt OxyContin promotional visits with physicians, cut sales force by half. DIA Daily 2018:16. [Ref.ID 102453]

11.

Mir de Francia R. Los fabricantes de opioides fijan a España como nuevo mercado. eldiario.es 2018:1. [Ref.ID 102452]

12.

Haffajee RL, Mello MM. Drug companies’ liability for the opioid epidemic. N Engl J Med 2017;377:2301-5. [Ref.ID 102168]

13.

Laatikainen O, Mietttunen J, Sneck S, Lehtiniemi H, Tenhunen O, Turpeinen M. The prevalence of medication-related adverse events in inpatients-a systematic review and meta-analysis. Eur J Clin Pharmacol 2017;73:1539-49. [Ref.ID 102145]

14.

Chang AK, Bijur PE, Esses D, Barnaby DP, Baer J. Effect of a single dose of oral opioid and nonopioid analgesics on acute extremity pain in the emergency department. A randomized clinical trial. JAMA 2017;318:1661-7. [Ref.ID 102137]

15.

Kyriacou DN. Opioid vs nonopioid acute pain management in the emergency department. JAMA 2017;318:1655-6. [Ref.ID 102136]

16.

Vélez AM. Juan Abelló pone a la venta su monopolio del opio en pleno debate sobre su venta descontrolada en EEUU . eldiario.es 2017:1. [Ref.ID 102121]

17.

Makary MA, Overton HN, Wang P. Overprescribing is major contributor to opioid crisis. BMJ 2017;359:j4792. [Ref.ID 102106]

18.

Patel P, Leeder JS, Piquette-Miller M, Dupuis LL. Aprepitant and fosaprepitant drug interactions: a systematic review. Br J Clin Pharmacol 2017;83:2148-62. [Ref.ID 102081]

19.

Armstrong D. Kentucky Senate president urges release of secret OxyContin records. STAT 2017:28 de junio. [Ref.ID 101657]

20.

Becker WC, Fiellin DA. Abuse-deterrent opioid formulations - Putting the potential benefits into perspective. N Engl J Med 2017;376:2103-5. [Ref.ID 101625]